GNSZ $.94 Media Advisory: GenSpera 2014 BIO Intern
Post# of 88933
Posted On: 06/30/2014 10:21:13 AM
GNSZ $.94 Media Advisory: GenSpera 2014 BIO International Presentation Available
http://finance.yahoo.com/news/media-advisory-...00165.html
GenSpera, Inc. (GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International presentation by Chairman and CEO, Craig Dionne, PhD from the 2014 BIO International Convention held June 24th in San Diego, California.
Dr. Dionne presented interim results from the Phase Ib and ongoing Phase II study for lead drug candidate, G-202.
Summary:
G-202 Data in Hepatocellular (HCC) Patients (Ph I and Ph II)
All patients previously progressed on, or were intolerant of, sorafenib
Outstanding clinical safety profile
Well tolerated with easily managed and predictable side effects
No effect on bone marrow!
80% of patients with stable disease (no tumor growth) at two months
50% of patients with stable disease for >/= 4 months
Long-term disease stabilization (>/= 9 months) in 15% of patients
One patient remains on treatment > 22 months
End of bone pain in one patient with vertebral metastasis
The full BIO presentation is available for view at:
http://www.genspera.com/press/140620_GNSZ_BIO...4_2014.pdf
About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.
G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.
For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.
About BIO
The 2014 BIO International Convention was held June 23-26 at the San Diego Convention Center in San Diego, California.
The BIO International Convention was hosted by the Biotechnology Industry Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. http://convention.bio.org/2014/
http://finance.yahoo.com/news/media-advisory-...00165.html
GenSpera, Inc. (GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International presentation by Chairman and CEO, Craig Dionne, PhD from the 2014 BIO International Convention held June 24th in San Diego, California.
Dr. Dionne presented interim results from the Phase Ib and ongoing Phase II study for lead drug candidate, G-202.
Summary:
G-202 Data in Hepatocellular (HCC) Patients (Ph I and Ph II)
All patients previously progressed on, or were intolerant of, sorafenib
Outstanding clinical safety profile
Well tolerated with easily managed and predictable side effects
No effect on bone marrow!
80% of patients with stable disease (no tumor growth) at two months
50% of patients with stable disease for >/= 4 months
Long-term disease stabilization (>/= 9 months) in 15% of patients
One patient remains on treatment > 22 months
End of bone pain in one patient with vertebral metastasis
The full BIO presentation is available for view at:
http://www.genspera.com/press/140620_GNSZ_BIO...4_2014.pdf
About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.
G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.
For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.
About BIO
The 2014 BIO International Convention was held June 23-26 at the San Diego Convention Center in San Diego, California.
The BIO International Convention was hosted by the Biotechnology Industry Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. http://convention.bio.org/2014/
(0)
(0)Scroll down for more posts ▼